- RecruitingPHASE1, PHASE2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
This study is testing new treatments, alone or in combination, for advanced prostate cancer that has spread and no longer responds to hormone therapy. Researchers want to see if these treatments are safe and effective in helping men with this condition.
For: Castration-Resistant Prostatic Cancer · MetastasisUnited States · Argentina · Australia - Active not recruitingPHASE2
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.
This study looks at new ways to treat a type of breast cancer called HER2-positive. We're testing if using special drugs (Herceptin and Perjeta) without chemotherapy first can shrink tumours effectively. We're also checking if scans can predict how well treatments work.
For: Breast CancerBelgium · France · Germany - Not yet recruitingPhase III
A large clinical trial testing different combinations of hormone treatments, with or without chemotherapy called docetaxel, in men with advanced prostate cancer whose prostate-specific antigen levels haven’t dropped enough after 6 months of treatment
This study, called INTENSIFY, looks at adding chemotherapy early to standard hormone treatment for men with advanced prostate cancer whose blood test (PSA) hasn't dropped enough. It aims to see if this helps them live longer.
For: Metastatic prostate cancerUnited Kingdom - Active not recruitingPHASE3
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
This study looks at a new combination of drugs, ceralasertib and durvalumab, for people with advanced lung cancer that has grown after previous treatments. It compares this new combination to a standard chemotherapy drug, docetaxel, to see which works better and is safer.
For: Advanced or Metastatic Non-Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruiting
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
This study looks at how men with advanced prostate cancer respond to darolutamide and hormone therapy, sometimes with chemotherapy, in real-world settings. It aims to understand treatment effectiveness, safety, and patient experiences to help improve care.
For: Metastatic Hormone-Sensitive Prostate CancerBelgium · Finland · France - Active not recruitingPHASE3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
This study is testing a new drug, AZD0901, for advanced stomach cancer or where the food pipe meets the stomach. It's for people whose cancer has Claudin18.2 protein and has already been treated before. Researchers want to see if AZD0901 works better and is safer than other treatments.
For: Gastric Cancer · Gastroesophageal Junction CancerUnited States · Brazil · Canada - RecruitingPHASE3
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
This study looks into a new drug, Datopotamab Deruxtecan (Dato-DXd), for advanced lung cancer. It compares Dato-DXd to a standard treatment, Docetaxel, in patients whose cancer has responded to previous treatments and has a specific marker called TROP2.
For: Non-small Cell Lung Cancer (NSCLC)United States · Australia · Austria - RecruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
This study is testing a new drug, daraxonrasib, for people with a specific type of advanced lung cancer (non-small cell lung cancer, or NSCLC) that has a RAS gene change. It compares the new drug to an existing chemotherapy, docetaxel, to see if it works better or has fewer side effects.
For: NSCLC (Non-small Cell Lung Cancer) · Non-Small Cell Lung Cancer · NSCLCUnited States · Australia · Belgium - RecruitingPHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
This study looks at new treatments for a type of womb cancer that has spread or returned. It compares a new drug combination (sac-TMT with pembrolizumab) against pembrolizumab alone to see if it helps patients live longer and keeps the cancer from growing.
For: Endometrial CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
This study looks at a new drug, pasritamig, with docetaxel to see if it helps men with advanced prostate cancer live longer without their cancer growing. It compares this combination to docetaxel alone.
For: Prostatic Neoplasms, Castration-ResistantUnited States · Australia · Belgium - RecruitingPHASE1
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
This study looks at a new drug, BNT116, for advanced lung cancer. It explores if BNT116 is safe, how much to give, and how well it works when used alone or with other treatments for different types of non-small cell lung cancer.
For: Non-Small Cell Lung CancerUnited States · Australia · Germany - RecruitingPHASE1, PHASE2
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
This study is testing new treatments for advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see how safe and effective a new drug, Opevesostat, is when given alone or with other medicines to men with this condition.
For: Prostatic Neoplasms, Castration-ResistantUnited States · Australia · Canada - RecruitingPHASE2
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
This study looks at a new drug, Inavolisib, combined with Enzalutamide for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It compares this combination to other standard treatments.
For: Metastatic Castration-Resistant Prostate CancerUnited States · Australia · Brazil - Active not recruitingPHASE3
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
This study compares a new cancer drug called sigvotatug vedotin with a standard treatment, docetaxel, for advanced non-small cell lung cancer that has previously been treated. It aims to see if the new drug works better and what side effects it might cause.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
This study is looking at a new treatment for early-stage lung cancer that can be removed with surgery. It combines standard chemotherapy with a newer drug called nivolumab. Researchers want to see if this combination helps people live longer without their cancer returning.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - Active not recruitingPHASE2
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
This study is for people with cancer that has spread, who are already benefiting from a specific medicine called trastuzumab emtansine (T-DM1) or other similar treatments in an earlier study. It allows them to keep receiving these important treatments for longer to see if they continue to help.
For: Neoplasm MetastasisUnited States · Australia · Belgium - Active not recruitingPHASE3
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
This study is testing a new drug, MRTX849 (adagrasib), for advanced lung cancer with a specific gene change (KRAS G12C). It compares it to a standard treatment, docetaxel, for people whose cancer has already been treated.
For: Metastatic Non Small Cell Lung Cancer · Advanced Non Small Cell Lung CancerUnited States · Australia · Austria - RecruitingPHASE2
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
This study is a research programme looking at new ways to treat cancer in children and young adults aged 1 to 39. It tests different medicines to find out how well they work and if they are safe.
For: Neoplasms · Child · AdolescentUnited States · Australia · Belgium - RecruitingPHASE3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
This study is looking at a new treatment, Xaluritamig, combined with Abiraterone, for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It compares this combination to standard treatments to see if it helps men live longer.
For: Metastatic Castration-resistant Prostate CancerUnited States · Australia · Austria - Active not recruitingPHASE3
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
This study looks at a new medicine, PF-06821497, combined with enzalutamide for men with advanced prostate cancer that has spread. It compares this combination to standard treatments like enzalutamide or docetaxel to see if it's safer and works better after previous abiraterone treatment.
For: Metastatic Castrate Resistant Prostate Cancer (mCRPC)United States · Argentina · Australia - Active not recruitingPHASE3
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
This study compares two treatments for advanced prostate cancer that has spread and no longer responds to hormone therapy. It tests if adding a new drug, capivasertib, to standard chemotherapy (docetaxel) works better than chemotherapy alone to help patients live longer and keep the cancer from growing.
For: Prostate CancerUnited States · Australia · Belgium - RecruitingPHASE3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
This study looks at new drug combinations for advanced or returning endometrial cancer that has a specific HER2 marker. It aims to see if these new treatments work better than standard chemotherapy by slowing down cancer growth.
For: Endometrial CancerUnited States · Australia · Austria - Active not recruitingPHASE3
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
This study looks at a new drug combination, acasunlimab and pembrolizumab, for a type of lung cancer that has spread or is advanced. It compares this combination to a standard chemotherapy, docetaxel, in people who have already had certain other treatments.
For: PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLCUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
This study is looking at a new treatment called pembrolizumab for advanced or recurrent womb cancer that has a specific genetic marker. It compares this new treatment to standard chemotherapy to see which works better and is safer for women who haven't had chemotherapy for this stage of cancer before.
For: Endometrial NeoplasmsUnited States · Australia · Belgium - Active not recruitingPHASE2, PHASE3
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
This study looks at new drug combinations for advanced non-small cell lung cancer that has progressed after standard treatments. It compares adding new medicines, cobolimab and dostarlimab, to docetaxel chemotherapy, to see if they work better together.
For: Lung Cancer, Non-Small CellUnited States · Argentina · Australia - RecruitingPHASE2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
This study is for cancer patients who are already taking part in another study using the drug adagrasib. It allows them to continue getting treatment if it's helping. It looks at how well adagrasib works long-term for various solid tumours, alone or with other cancer medicines.
For: Solid TumorsUnited States · Australia · Belgium - RecruitingPHASE3
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
This study is looking at a new treatment (BNT323) for women with advanced womb cancer that has come back. It compares BNT323 to standard chemotherapy to see if it works better at shrinking tumours and keeping the cancer from growing.
For: Endometrial CancerUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
This study is looking at new ways to treat advanced prostate cancer that has spread. Researchers are testing different medicines to see how safe they are, if they have side effects, and how well they work in men whose cancer hasn't responded to previous treatments.
For: Metastatic Prostate CancerUnited States · Australia · Germany - RecruitingPHASE3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
This study is testing a new medicine, ifinatamab deruxtecan (I-DXd), for men with advanced prostate cancer that has spread and isn't responding to hormone therapy. We want to see if I-DXd helps men live longer and keeps their cancer from growing compared to standard chemotherapy.
For: Prostate Cancer · Prostatic NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
This study looks at a new drug, BMS-986365, for men with prostate cancer that has spread and is no longer responding to hormone treatment. We want to see if it works better and is safer than standard treatments chosen by doctors.
For: Metastatic Castration-resistant Prostate CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
This study looks at a new drug, selumetinib, combined with standard chemotherapy (docetaxel) for a specific type of advanced lung cancer. It aims to see if this combination works better than chemotherapy alone for patients whose cancer has the KRAS gene mutation.
For: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVUnited States · Argentina · Australia - RecruitingPHASE3
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
This study looks at a new drug, gotistobart, for advanced non-small cell lung cancer that has worsened after previous PD-1/PD-L1 treatment. It compares gotistobart to standard chemotherapy (docetaxel) to see if it can help people live longer.
For: Non Small Cell Lung CancerUnited States · Australia · Belgium - Active not recruitingPHASE2
Study of Novel Treatment Combinations in Patients With Lung Cancer
This study looks at new drug combinations to treat lung cancer. It has three parts: for cancer that has spread, cancer that has grown despite previous treatment, and earlier-stage cancer that can be removed by surgery.
For: Lung Cancer · Advanced or Metastatic Non-Small-Cell Lung Cancer · Resectable Non-Small-Cell Lung CancerUnited States · Brazil · Hong Kong - RecruitingPHASE3
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
This study looks at a new drug, 177Lu-TLX591, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. It compares this new drug combined with standard treatments to standard treatments alone.
For: Metastatic Castration-resistant Prostate CancerUnited States · Australia · Canada - Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
This study compares a new medicine, Sacituzumab Tirumotecan, with standard chemotherapy for advanced lung cancer. It’s for people whose cancer has specific genetic changes and has already been treated. We're looking to see if the new medicine helps people live longer and keeps their cancer from growing for longer.
For: Non-small Cell Lung Cancer (NSCLC)United States · Australia · Brazil - RecruitingPHASE3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
This study is for people with advanced lung cancer that has stopped responding to certain immune system treatments. It tests a new treatment called OSE2101 against a standard chemotherapy, Docetaxel, to see which works better. This is a large study trying to find new ways to help patients.
For: Patients With Non-Small Cell Lung CancerUnited States · Belgium · Canada - Active not recruitingPHASE2
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
This study is looking at new combinations of medicines for advanced lung cancer. It aims to see how well different immunotherapy treatments work together and how safe they are for patients. The goal is to find better ways to treat this type of lung cancer.
For: Advanced Non-Small Cell Lung CancerUnited States · Australia · France - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy after surgery for certain types of womb cancer (endometrial cancer). We want to see if this combination helps stop the cancer from coming back and helps people live longer compared to chemotherapy alone.
For: Endometrial NeoplasmsUnited States · Argentina · Austria - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
This study looks at a new drug, Giredestrant, combined with an existing treatment called Phesgo, for advanced breast cancer. It aims to see if this new combination is safe and works better than Phesgo alone for people with specific types of breast cancer.
For: Locally Advanced or Metastatic Breast CancerUnited States · Argentina · Belgium - Active not recruitingPHASE2
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
This study compares a new treatment, 177Lu-PSMA-617, with standard chemotherapy (docetaxel) for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new treatment can better slow cancer growth.
For: Prostate CancerCanada - RecruitingPHASE2
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
This study is looking for new treatments for advanced squamous non-small cell lung cancer that hasn't responded to usual treatments. Researchers are testing new medicines called antibody drug conjugates (ADCs) to see if they can shrink the cancer and if they are safe.
For: Lung NeoplasmUnited States · Chile · China - Active not recruitingPHASE2, PHASE3
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
This study, called STAMPEDE, looks for better ways to treat prostate cancer that is spreading or has a high chance of spreading. It tests new treatments against standard ones to help men live longer and have a better quality of life.
For: Prostate CancerSwitzerland · United Kingdom - Active not recruitingPHASE3
Detect V / CHEVENDO (Chemo vs. Endo)
This study compares different treatments for advanced breast cancer that has spread. It aims to see if a combination of targeted therapies and hormone therapy works better than targeted therapies and chemotherapy, while also keeping quality of life high.
For: Metastatic Breast CancerGermany - Active not recruitingPHASE3
Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT
This study looks at treating a certain type of throat cancer with chemotherapy and radiotherapy to try and save the voice box. We're comparing two ways of giving chemotherapy to see which works better to keep the voice box working for longer.
For: Head and Neck Squamous Cell CarcinomaFrance - RecruitingPHASE2
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
This study is for people with advanced lung cancer that has spread. It tests new treatments using a drug called Visugromab, combined with Nivolumab and sometimes Docetaxel, to see if they can work better than existing options.
For: Metastatic Non-Squamous Non-Small Cell Lung Cancer · Adult Solid TumorUnited States · Germany · Italy - Active not recruitingPHASE3
A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients
This study compares two ways of giving a prostate cancer drug, Docetaxel, along with standard treatments Darolutamide and ADT. It aims to find out which schedule causes fewer serious side effects in men with advanced prostate cancer.
For: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Austria · Germany - Active not recruitingPHASE3
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
This study compares a new treatment, Atezolizumab, to standard care for patients with early-stage lung cancer after surgery and chemotherapy. It aims to see if Atezolizumab can prevent the cancer from returning and help people live longer.
For: Non-Small Cell Lung CancerUnited States · Australia · Belgium - Active not recruitingPHASE2, PHASE3
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations for advanced non-small cell lung cancer. It aims to find out how safe and effective these treatments are for people whose cancer has specific genetic changes, using blood tests to identify these changes.
For: Non-Small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
This study looks at new treatments for ovarian cancer that has come back and is resistant to platinum-based chemotherapy. It combines existing drugs like paclitaxel and bevacizumab with a new drug called pembrolizumab, hoping to stop the cancer from growing for longer.
For: Ovarian Cancer · Carcinoma, Ovarian Epithelial · Fallopian Tube NeoplasmsUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
This study is testing a new medicine, Anvumetostat, for people with advanced cancers that are missing a specific gene called MTAP. Researchers want to find the safest dose, see how well it works, and understand its side effects, sometimes given with another cancer drug called Docetaxel.
For: Advanced MTAP-null Solid TumorsUnited States · Australia · Austria